Market revenue in 2023 | USD 339.4 million |
Market revenue in 2030 | USD 1,999.3 million |
Growth rate | 28.8% (CAGR from 2023 to 2030) |
Largest segment | Pre-clinical |
Fastest growing segment | Pre-clinical |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pre-clinical, Clinical |
Key market players worldwide | Lonza Group Ltd, Catalent Inc, Cytiva, Samsung Electronics Co Ltd, Thermo Fisher Scientific Inc, Novartis AG ADR, Wuxi AppTec Co Ltd, AGC Inc, OmniAb Inc, Rentschler Biopharma SE, Charles River Laboratories International Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy cdmo market will help companies and investors design strategic landscapes.
Pre-clinical was the largest segment with a revenue share of 66.21% in 2023. Horizon Databook has segmented the Japan cell and gene therapy cdmo market based on pre-clinical, clinical covering the revenue growth of each sub-segment from 2018 to 2030.
There is a rising demand for biopharmaceutical drugs in Japan to diagnose & treat various chronic diseases. Japan is one of the world’s largest pharmaceutical markets, actively involved in improving access to biopharmaceutical drugs.
Moreover, rapid advancements in drug delivery technology, such as targeted drug delivery & sustained-release dosage forms, are expected to drive the cell and gene therapy CDMO market growth. Some of the major players in the market are Corden Pharma, Wuxi AppTec, Cambrex Corporation, Recipharm AB, and Lonza.
Several key players have expanded their contract manufacturing offerings in Japan to increase their product capacity to produce highly potent pharmaceutical dosage forms. For instance, in December 2023, Japanese multinational Ajinomoto Co. was expected to acquire Forge Biologics, a gene therapy developer and manufacturer, for USD 554 million. The deal, valued at USD 620 million on a cash-free and debt-free basis, was expected to close in Q4 2023. Ajinomoto aims to enhance its capabilities with Forge’s expertise in gene therapy.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan cell and gene therapy cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Japan cell and gene therapy cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account